Menopause clinic marketing: claims and ad rules

Menopause care has moved into the spotlight. More practices now offer dedicated menopause visits, hormone therapy and follow-up care, and many patients search online before they ever book. That attention brings a marketing problem: the topic is full of strong claims, a lot of them about compounded “bioidentical” hormones, and a federal label change in late 2025 is easy to overstate.

This guide covers what is specific to menopause and hormone therapy clinics: what the FDA changed and what it did not, what the FDA says about compounded hormones, how to handle claims and patient stories, Google’s rules on prescription drug terms and how to keep intake private. If your clinic also treats men with testosterone, see our guide to testosterone clinic marketing, which covers controlled substance and telehealth rules this article does not repeat. Clinics asked to add laser or radiofrequency vaginal treatments should read our guide to vaginal rejuvenation advertising rules first. Thyroid claims have their own guide; see thyroid clinic marketing.

This is general information, not legal or medical advice. Sources cited were checked on October 29, 2026: the FDA drug safety statement on menopausal hormone therapy labeling (content current as of February 12, 2026), the FDA press announcement of November 10, 2025, the FDA Menopause page (content current as of December 14, 2023), the FDA pages on compounded drug risks and the NASEM study of compounded bioidentical hormone therapy, the FTC Health Products Compliance Guidance, 16 CFR 255.2, 45 CFR 164.508, and Google Ads healthcare, restricted drug terms, prescription drug services and personalized advertising policies. Rules change, so check the current versions and talk to your own counsel.

Start with what menopause care is

The FDA’s Menopause page for patients says a woman has reached menopause when she has not had a period for 12 months in a row, and that this often happens between ages 45 and 55. It lists symptoms that may come before it, including changes in periods, hot flashes, night sweats that can disrupt sleep, vaginal changes and bone thinning. It also says treatments include hormone therapy and non-hormonal therapy, and that patients should talk with their provider if symptoms interfere with their usual activities.

That framing is a good foundation for a clinic website. Patients come in with very different symptoms and goals, and some are not candidates for hormones at all. Pages built around the evaluation and the full range of options are more useful to them and easier to defend than pages built around one product.

A first visit page that explains what the provider asks about, what the exam covers and what testing your providers may order.
A treatment options page that describes hormone and non-hormonal options in plain words, and says the provider recommends a plan after an evaluation.
A risks and questions section that tells patients to discuss benefits and risks with their provider, without listing doses or promising outcomes.
A cost page that shows visit prices, what follow-up costs and whether medicines and lab work are billed separately.

The 2025 boxed warning change, and what it does not let you say

On November 10, 2025, the FDA announced that it was initiating the removal of broad boxed warnings from menopausal hormone therapy products. Its drug safety statement lists the requested changes to the prescribing information. For all menopausal hormone therapy products, systemic and local vaginal, the FDA asked to remove the boxed warning language on cardiovascular diseases, breast cancer and probable dementia, and to remove the recommendation to use the lowest effective dose for the shortest time.

The same statement is just as clear about what stays. For systemic products, the boxed warning about endometrial cancer is retained in estrogen-alone products, and information about cardiovascular disease and breast cancer warnings is retained in the labeling. The FDA also asked to add a consideration of starting hormone therapy for moderate to severe hot flashes and night sweats in women under 60 or within 10 years of menopause. The page, content current as of February 12, 2026, says the prescribing information has been updated on these products.

For marketing, that leads to a few firm lines:

Do not say the FDA declared hormone therapy safe. The FDA changed what the boxed warning says. Warnings and risk information remain in the labeling, and one boxed warning remains for some products.
Do not borrow statistics from press coverage. If a number about benefits is not something your clinic can support for your own patients and services, it does not belong in your ads or pages. See the claims section below.
Do not stretch the change to products it does not cover. The label changes apply to FDA-approved menopausal hormone therapy products and their prescribing information. Compounded preparations are not FDA-approved and have no FDA-approved label to change.
Do keep the decision with the prescriber. Language like “talk with your provider about whether hormone therapy is right for you” matches how the FDA itself frames treatment decisions.

Compounded “bioidentical” hormones: what the FDA says

Many menopause clinics work with compounding pharmacies, and compounded hormones are where the riskiest marketing claims tend to appear. The FDA has been direct about this on several pages. For pellets in particular, see our guide to hormone pellet therapy marketing.

Not FDA-approved. The FDA’s page on the risks of compounded drugs says compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. It also says compounded drugs can serve an important medical need for some patients.
No evidence they are safer. On its Menopause page, the FDA says many products marketed as “bioidentical hormones” are compounded drugs, and that it does not have evidence that compounded bioidentical hormones are safe and effective, or safer or more effective than FDA-approved hormone therapy. It recommends that women use hormone therapies that are FDA-approved.
Bioidentical is not a category of its own. The same page notes that the FDA has approved drugs containing hormones that are identical to the hormones women make naturally in their reproductive years. So “bioidentical” does not separate compounded products from approved ones.
Estriol. The FDA says it does not have evidence that drugs containing estriol are safe and effective or are “safer forms of estrogen”, that there are no FDA-approved drugs containing estriol, and that marketed drugs containing estriol are compounded drugs.
The NASEM review. The FDA asked the National Academies of Sciences, Engineering, and Medicine to study compounded bioidentical hormone therapy. The FDA page on that study says the report, delivered July 1, 2020, found a lack of rigorous evidence of safety and effectiveness from well-designed clinical studies, found that most information came from low quality data such as anecdotal claims and testimonials, and concluded that wide-spread use poses a public health concern. The FDA page also notes these products are often advertised as natural, safer or free of the side effects of approved hormones.

Those statements map directly onto the claims to avoid. Do not call compounded hormones natural and therefore safer, do not say they have fewer side effects or no side effects, do not imply they are equivalent to or better than FDA-approved products, and never describe a compounded preparation as FDA-approved. If your clinic prescribes compounded hormones for patients who need them, say that plainly and say what the provider weighs when deciding. We cover the same FDA pattern for another drug class in our guide to weight loss clinic marketing.

Bone health after menopause has its own rules for screening pages, heel scans and supplement claims. Our guide to osteoporosis and bone density clinic marketing covers them.

Claims, testimonials and patient stories

The FTC Health Products Compliance Guidance says health claims need competent and reliable scientific evidence, and that individual experiences such as testimonials are never enough to substantiate claims about a product’s effects. The evidence has to fit the claim you actually make, for the treatment you actually offer.

Menopause marketing drifts quickly into lines that would need strong support, and often have none:

Anti-aging promises. “Turn back the clock”, “feel like you did at 30” or “reverse aging” are effect claims about a medical treatment.
Hormone balancing. “We balance your hormones” sounds harmless but implies a measurable outcome. Describe what the provider does instead: evaluation, options and follow-up.
Prevention claims. Saying hormone therapy prevents heart disease, dementia or other conditions is a disease claim. Leave benefit and risk discussions to the visit and the product labeling.
Weight, mood and libido claims. These are some of the most common promises in this space and some of the hardest to support for a specific clinic’s patients.

Patient stories need the same care. Under 16 CFR 255.2(b), an endorsement about a key attribute of a product or service will likely be read as representing what people will generally achieve. If you cannot show that a story is representative, you need to clearly disclose what patients can generally expect. A testimonial that uses identifiable patient information also needs a HIPAA authorization under 45 CFR 164.508(a)(3) when it is used for marketing. Our guide to patient testimonials and before and after photos covers the process.

Google Ads: drug terms, prescribing and audiences

Three Google policies shape menopause clinic campaigns in the United States.

Restricted drug terms. Google’s Restricted drug terms policy says that for campaigns targeting the United States, you may use prescription drug terms in ads and landing pages for promotional purposes in accordance with local laws, without certification, but you must be certified to keyword-target those terms. Since our rule is to keep drug names out of clinic marketing anyway, most clinics can write ads around the visit and the condition rather than the medicine.
Prescription drug services. Google restricts ads for services related to online prescribing, dispensing and sale of prescription drugs, including telemedicine providers, and says advertisers must be certified to serve them. Google also says it errs on the side of caution for landing pages that appear to facilitate online prescribing. If your clinic prescribes hormone therapy through virtual visits, check the certification requirements before launching; our guide to telehealth marketing for practices has more.
Personalized advertising. Health is a sensitive interest category under Google’s personalized advertising policy, and the policy says advertisers promoting products and services in sensitive interest categories cannot use advertiser-curated audiences, such as customer match and your data segments. Plan menopause campaigns around search intent and location, not lists of patients or site visitors.

Meta and other platforms have their own health rules, covered in our guide to Facebook and Instagram ads for medical practices.

Privacy for menopause intake

Menopause intake forms collect detailed reproductive and sexual health information. Treat every form, chat and booking page as a place where protected health information may be entered. Keep advertising and analytics tags off pages that collect symptoms, and review what your scheduling and form tools pass to third parties; our guides to HIPAA and website contact forms and tracking pixels on practice websites go through this step by step.

Follow-up marketing needs the same care. Under 45 CFR 164.508(a)(3), using protected health information for marketing generally requires the patient’s written authorization, with narrow exceptions for face-to-face communications and promotional gifts of nominal value. A newsletter to past patients about a new hormone service is the kind of message to check with counsel before you send it.

Illustration: rewriting a menopause service page

Illustration. A clinic’s draft headline reads “Natural bioidentical hormones: safer than synthetic HRT, now that the FDA removed the black box warning.” Each part of that line runs into a source above. “Natural” and “safer” are the claims the FDA says it has no evidence for. “Bioidentical” does not distinguish compounded products from approved ones. And the label change applied to FDA-approved products, kept other warnings in place and did not declare any product safe.

A version that holds up: “Menopause care built around your symptoms. A full evaluation with a clinician who explains hormone and non-hormonal options, the benefits and risks of each, and what follow-up looks like.” The page then describes the visit, lists costs and invites the patient to book. It promises an experience the clinic controls, not a clinical result.

Common mistakes

Saying the FDA “cleared” or “approved” hormone therapy as safe because of the 2025 label change.
Calling compounded hormones FDA-approved, natural and safer, or free of side effects.
Presenting estriol as a safer estrogen.
Quoting benefit percentages from news coverage as if they were your clinic’s results.
Running testimonials about weight loss, mood or libido without substantiation or a typical results disclosure.
Building remarketing audiences from visitors to menopause pages.
Placing ad tracking tags on symptom intake forms.

How we help

We build menopause and women’s health service pages that describe the evaluation, the options and the costs in plain words, with claims matched to your sources. Our healthcare SEO work focuses on the questions patients actually search, our Google Ads for practices service plans campaigns inside the healthcare and drug term policies, and our medical website design keeps intake forms free of advertising tags. We do not promise rankings, leads or patient outcomes, and your clinicians approve every clinical statement before it goes live.

Frequently asked questions

Did the FDA remove all warnings from hormone therapy?

No. The FDA requested removal of the boxed warning language on cardiovascular diseases, breast cancer and probable dementia, but its statement says the boxed warning about endometrial cancer stays for systemic estrogen-alone products, and information about cardiovascular disease and breast cancer warnings stays in the labeling for systemic products.

Can we advertise compounded bioidentical hormones?

You can describe that your providers may prescribe compounded preparations when appropriate, but avoid saying or implying they are FDA-approved, natural and therefore safer, or more effective than approved products. The FDA says compounded drugs are not FDA-approved and that it has no evidence compounded bioidentical hormones are safer or more effective than FDA-approved hormone therapy.

Can we use the word bioidentical?

Use it carefully and accurately. The FDA notes that it has approved drugs containing hormones identical to those women make naturally, so the word alone does not mean compounded, and it does not support claims of extra safety.

Can our Google ads mention hormone therapy?

Google allows prescription drug terms in US ads and landing pages without certification but requires certification to keyword-target them, and it requires certification for online prescribing services such as telemedicine. Health is also a sensitive category for personalized ads. Check the current policies before launch.

Can we share patient success stories?

Only with a HIPAA authorization when identifiable patient information is used for marketing, and with care under 16 CFR 255.2(b): if the story is not representative, you must clearly disclose what patients can generally expect. Testimonials cannot substantiate a health claim on their own.

Menopause clinic marketing: hormone therapy claims, compounded hormones and ad rules